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Abstract 
Introduction: Psoriasis is a chronic condition whose therapeutic armamentarium is 
increasingly being discussed, particularly when compared to past decades. The use 
of biologic agents has profoundly changed the history of this disease, as well as the 
management of psoriatic patients. Due to the enormous interest in psoriasis, as 
demonstrated within the scientific community and pharmaceuticals, new therapeutic 
targets have been identified and novel patented therapeutics are being tested.  
Areas covered: This review sought to give an overview of small molecules and 
antibodies patented in the last five years for the treatment of psoriasis. Therapeutic 
agents either in the early or advanced phase of development have been described, 
primarily based on a systematic search using the Pubmed Medline database. 
Expert opinion: Though the recent introduction of new antipsoriatic agents has 
facilitated the management of long-term psoriasis, there is still a strong desire for 
alternative therapeutic options. Indeed, there remain unmet needs regarding safety 
and efficacy of psoriasis treatment that should be addressed. In this context, recently 
patented drugs may prove valid, interesting, and promising within the therapeutic 
paradigm. 
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D
ow
nl
oa
de
d 
by
 [A
nd
rea
 C
hir
ico
zz
i] 
at 
14
:01
 08
 Ju
ne
 20
16
 
4  
Article highlights  
• Although biologic therapies profoundly modified the management of 
psoriasis, still unmet needs remain. 
• Novel patented drugs are being tested for the treatment of psoriasis, both 
small molecule agents and biologicals. 
• Intracellular signaling molecules (JAK-STAT, PDE4, A3 adenosine 
receptor, S1P, and aka activating protein 1) as well as soluble mediators 
(i.e. IL-23, IL-17, VEGF-A), receptors (i.e., IL-17R), and surface 
costimulator molecules (i.e., CD6) have been recognized as therapeutic 
targets. 
• Conceptually, bispecific agents could represent a revolutionary approach 
as current biologic therapeutics target one single molecule. 
• The development of more selective and more effective drugs that 
maintain very high standards of safety, compared to previously approved 
biologic agents, is the result of an increased understanding in the 
psoriasis pathogenic mechanism. 
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1. Introduction 
Psoriasis is a chronic skin disorder whose pathogenic mechanism has been deeply 
investigated in the last three decades, revealing a crucial role of both adaptive and 
innate immunity. The immune activation may be triggered by various mechanisms 
including the presence of self-molecules identified as auto-antigens by autoreactive T 
cells, both CD4+ and CD8+ T cells [1]. However, early steps of the pathogenesis 
might involve plasmacytoid and myeloid dendritic cells (pDCs and mDCs, 
respectively) activated by self-DNA or RNA combined with LL-37 or by chemerin [2-
5]. Psoriasis skin inflammation is driven by multiple immune circuits amplified by 
keratinocytes that recruit T cells, neutrophils, DCs, and other immune cells, 
producing chemokines and AMPs acting as chemoattractans.  
Though key-cytokines such as IL-22, TNF±, and IFN-³  drive pathogenic pathways, 
which resulted upregulated in psoriasis, mounting evidence has proved the crucial 
role of the IL-23/IL-17 axis [6]. 
In this setting, multiple therapeutic targets may be identified: chemokines and their 
receptors, cytokines and their receptors, adhesion molecules, cell surface antigens, 
transcription factors, and other intracellular signal transducers.  
 
2 Psoriasis pathogenesis: identification of selective therapeutic targets  
 2.1 Key cells contributing to psoriasis: T cells 
 
Various subtypes of T cells abundantly infiltrate lesional psoriatic skin including ³ ´ + T 
cells and CD4+ T cells, localized within the dermis, and CD8+ T cells infiltrating the 
epidermis [7-9]. Beside activated resident T cells, the psoriatic plaque includes 
migrating T cells from the blood circulation. These cells reach lesional skin because 
of the interaction between leukocyte function-associated antigen-1 (LFA-1), a 
member of ² 2 integrin family, and intracellular adhesion molecule-1 (ICAM-1), that 
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plays a critical role not only in mediating cell adhesion and leukocyte transmigration, 
but also in increasing T-cell receptor signaling.  
Distinct T cell subsets contribute to psoriasis phenotype [10]. Specifically, CD4+ T 
cells producing pathogenic cytokines such as IL-17, IL-22, and IFN³ , are identified as 
Th17, Th22, and Th1, respectively. There are also CD8+ T cells, which are able to 
produce the same spectrum of cytokines and are named Tc17, Tc22, and Tc1. 
 
2.1.1 γδ+ T cells 
These cells have been recently described as important contributors in psoriasis 
pathogenesis as they were found significantly increased in lesional psoriatic skin 
compared to healthy controls. Notably, the total number of IL-17+/ ³ ´ + T cells was 
higher than ³ ´ - T cells [9]. Furthermore, they are able to produce IL-17 if stimulated 
by IL-23, as they do express IL-23R as well as CCR6, similarly to other IL-17-
secreting T cells [11]. 
 
2.1.2 Innate Lymphoid Cells 
This newly described immune cell subtype still needs to be fully characterized both 
morphologically and functionally. Indeed, they are thought as precursors of NK cells, 
as bearing NK markers (such as NKp44). Functionally, three ILC subtypes may be 
distinguished based on their cytokine production: ILC1, producing IFN-³ , ILC2, 
producing IL-4, and ILC3, producing IL-17 and IL-22, and expressing IL-23R. This 
latter subtype is found increased in both blood and lesional skin of psoriatic patients 
[12].  
 
2.1.3 Plasmacytoid and myeloid DCs 
DCs may be considered crucially involved in the early steps of the inflammatory 
cascade. pDCs express BDCA-2, CD123, HLA-DR, whereas they do not bear CD11c 
antigen [13]. When stimulated by toll-like receptor agonists or by chemerin they are 
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able to secrete interferons, particularly IFN-±, a crucial event in the initiation of the 
inflammatory psoriasis cascade [13]. 
Dermal myeloid DCs (mDCs), which are greatly increased in lesional psoriatic skin, 
do express CD11c and they are negative for BDCA1. mDCs might be activated by 
different triggers which include toll-like receptor (TLR) agonists, and IFN-±. Once 
they are activated, they may differentiate into highly inflammatory DCs producing 
TNF±, nitric oxide, IL-20, and the so-called p40 cytokines, IL-12 and IL-23 [14]. 
 Secreting IL-12, they drive the differentiation of IFN-³ + T cells, while 
producing IL-23, they sustain and amplify an IL-17+ T cell response [15]. 
 
2.1.3 Keratinocytes 
Keratinocytes are considered the key-responding tissue cells to the cytokine 
microenvironment as: (i) they proliferate through an altered differentiation process 
stimulated by mitogenic cytokines such as IL-22, IL-20, IL-19, and IL-24; (ii) they are 
immunologically active secreting: antimicrobial peptides (i.e., HBD2, LCN2, S100A 
family, cathelicidins) that act as chemoattractans, cytokines (TNF±, IL-6, IL-1² ), and 
chemokines including CCL20, CXCL-9, -10, -11, and CXCL-8 that stimulate 
neutrophil recruitment [16,17].  
 
2.2 Transcription factors  
Cell activation reflects the upregulation of multiple signaling pathways involving 
peculiar transcription factors or enzymes, such as Janus kinase-signal transducer 
and activator of transcription (JAK-STAT), phosphodiesterase (PDE)-4, and 
sphingosine 1-phosphate (S1P) receptor.  
JAK-STAT signaling is considered one of the most important pathways in psoriasis 
as it transduces intracellular signals induced by a wide array of cytokines and growth 
factors [18,19]. Particularly, it plays a critical role in mediating inflammatory immune 
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responses by converting cytokine signals into genomic responses and, thus, 
regulating immune cell proliferation and differentiation [18,19].  
Overall, JAK tyrosine kinases consist in a family of four non-receptor tyrosine 
kinases, namely JAK1, JAK2, JAK3 and Tyk2 that act in pairs in the 
intracytoplasmatic portion of the cytokine receptor. JAK signaling is conventionally 
transduced to an array of transcription activators, the STAT family, that includes 7 
members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6 [20]. 
Because several cytokines such as IFN-±, IFN-³ , IL-2, IL-6, IL-12, IL-15, IL-19, IL-20, 
IL-22, IL-23, and IL-24 involved in psoriasis pathogenesis act through JAK/STAT 
signaling pathways, its blockade has been recently proved beneficial in clearing 
psoriasis [21].  
Another highly expressed intracellular enzyme is PDE-4 that is found in activated 
inflammatory cells (i.e. T cells, DCs) as well as skin tissue cells (i.e., keratinocytes) 
[22]. Additionally, activated lymphocytes express S1P that is a sphingolipid required 
to exit the lymphoid tissue and enter the bloodstream via a chemotactic gradient [23].  
In this crosstalk involving immune and tissue cells, a plethora of therapeutic targets 
may be identified for emerging, recently-patented drugs. Particularly, key-cytokines, 
namely TNF± and IL-17, demonstrated to be crucial in mediating the most relevant 
inflammatory circuits; and intracellular signaling pathway transducers (i.e., JAK-
STAT, PDE4, and S1P) are involved in the pathways driving inflammation and/or 
proliferation. In this review, we will report patent drugs including small molecules and 
monoclonal antibodies that are being developed and that may represent promising 
antipsoriatic therapies in the future. 
  
3. Small molecules 
The so-called small molecule drugs are characterized by low molecular size. 
Compared to biologic therapy, their production is less expensive and allow an oral or 
topical administration. These therapies are able to neutralize the effects of cytokines 
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9  
or cytokine receptors blocking intracellular targets such as transcriptional factors or 
enzymes. Moreover, these products could alleviate many of the challenges that are 
associated with biologics, namely price, difficulty in production, clinical 
contraindications, method of administration, and difficulty in producing a significantly 
less expensive counterpart when patents expire. 
Several group of small molecules are under evaluation for the treatment of psoriasis 
including: 1) JAK inhibitors, 2) the PDE 4 inhibitors, 3) A3 adenosine receptor 
agonists, 4) TNF± inhibitors, 5) S1P agonist, and 6) aka activating protein 1 (AP-1). 
 
3.1 JAK inhibitors 
The JAK protein tyrosine kinase family is constituted by cytoplasmic PTKs that play a 
pivotal role in cytokine signal transduction pathways through association with various 
cytokine receptors by activation of the latent forms of STATs involved in the 
pathogenesis of psoriasis. 
Protein kinases like JAKs are enzymes, which transfer phosphate groups from 
adenosine triphosphate (ATP) or guanosine triphosphate to hydroxyl groups of amino 
acids of their substrates. Tyrosine kinases phosphorylate tyrosine residues and 
blocking their enzymatic activity has proved to be a successful strategy [24]. JAK1 is 
involved in the activation of IFN-³ , IL-6 and IL-10 receptors. JAK2 primarily 
associates with hematopoietic receptors, but also with IL-12 and IL-23 receptors. 
JAK3 is the most specific type as it acts only with receptors that contain the common 
³  chain (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21), whose signals are crucial for 
lymphocyte activation, proliferation and function [25-26]. Because JAK3 is crucial in 
transducing signals of relevant pathogenic cytokines, such as IL-23, the development 
of small molecule drugs targeting this kinase were thought to have a therapeutic 
relevance, as subsequently demonstrated in clinical trial phases. 
Tofacitinib is an inhibitor of the JAK1 and JAK3 signaling pathway and it is one of the 
first JAK inhibitors used in humans. It has been reported to be a safe and effective 
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therapy for ulcerative colitis [26, 27] and rheumatoid arthritis [28,29] and results of 
the phase II and III studies on psoriasis have been published [30,31]. The phase II 
dose-ranging study showed that at week 12, PASI75 response (at least 75% 
improvement of PASI score compared to the baseline) rates were significantly higher 
for all tofacitinib-treated patients compared with placebo. At week 12, PASI75 
response was reached in 67% of patients receiving 15 mg of tofacitinib daily with the 
most frequently reported adverse events (AEs) represented by upper respiratory tract 
infection [30]. A phase III, randomized, multicentre, double-dummy, placebo-
controlled, 12-week study, tested non-inferiority of tofacitinib 5 mg and 10 mg, 
compared with high-dose etanercept or placebo. Patients were randomly assigned in 
a 3:3:3:1 ratio to receive tofacitinib 5 mg or 10 mg BID at about 12 hours intervals, 
etanercept 50 mg subcutaneously twice weekly, or placebo [31]. Conversely to 5 mg 
tofacitinib BID, the higher dose, 10 mg BID was non-inferior to etanercept 50 mg 
twice weekly in terms of PASI 50, PASI 75, and PASI 90 achievement, as well as 
PGA response [31]. The adverse event rates over 12 weeks were similar for 
tofacitinib and etanercept. As stated by the Authors, tofacitinib 10 mg twice-daily 
showed similar efficacy and safety to etanercept in the short-term period investigated 
(12 weeks). Although, tofacitinib could represent a valid therapeutic option for 
patients with moderate-to-severe plaque psoriasis, FDA denied the approval for the 
treatment psoriasis, pausing its development because the higher dose (10 mg) of 
tofacitinib, which resulted non-inferior to etanercept, arose safety concerns and was 
not considered to have an adequate risk-to-benefit ratio.  
Due to their small molecular size, tofacitinib has also been studied as topical 
treatment for psoriasis. In a vehicle-controlled phase IIa trial studying a topical 
tofacitinib ointment formulation, Ports et al. reported the psoriasis patients treated 
with tofacitinib 2% ointment 1 BID present an improvement in the target plaque 
severity score at week 4 [32]. 
Another JAK inhibitor is ruxolitinib that preferentially inhibits JAK1 and JAK2 and it 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 C
hir
ico
zz
i] 
at 
14
:01
 08
 Ju
ne
 20
16
 
11  
has been firstly investigated as topical formulation (INCB018424, Incyte) for use in 
psoriasis [33]. A Phase 2a trial comparing topical INCB018424 0.5%, 1% and 1.5% 
cream in a double-blind, vehicle-controlled trial was shown to be safe and effective 
with improvement in total lesion score, PGA and PASI [34].  
There are additional JAK inhibitors undergoing investigation for the treatment of 
moderate-to-severe psoriasis [35], such as baricitinib (INCB-28050/LY3009104), a 
JAK1 and JAK3 inhibitor, that is being examined in a phase IIb dose ranging study 
[36]. 
3.2 PDE4 inhibitors 
Apremilast is an orally available, specific inhibitor of PDE-4 that works intracellularly 
[37]. PDE4 inhibitors have garnered much investigation as potential modulators of 
inflammatory signaling. Apremilast has demonstrated the ability to reduce cellular 
expression of pro-inflammatory markers that are usually elevated in psoriatic tissue, 
such as IL-23 and TNF±, while simultaneously promoting expression of anti-
inflammatory mediators such as IL-10 [38, 39]. Apremilast (Otezla®, Celgene 
Corporation, Summit, New Jersey) was approved by the US FDA for the treatment of 
patients with moderate to severe plaque psoriasis for whom phototherapy or 
systemic therapy is appropriate and for the treatment of patients with active PsA at 
the dosage of 30 mg BID. The investigators found, in a Phase II, multicentre, dose-
comparison study involving patients with moderate-to-severe disease, that at week 
16, PASI75 was achieved in 29% of patients receiving 20 mg and 41% of patients 
receiving 30 mg apremilast BID. AEs (96%) were mild or moderate and no apparent 
effects of apremilast were observed on haematological, urinalysis, serum chemistry, 
or electrocardiographic tests [40]. Phase III studies investigated the safety and 
efficacy of the 30 mg BID dose [41]. The preliminary findings from ESTEEM-1, 
included 844 patients receiving oral apremilast 30 mg BID, reported a PASI75 
response of 33% at week 16 compared to the placebo response of 5.3%. ESTEEM 1 
is the first phase III study confirming the efficacy of apremilast in terms of PASI score 
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and in pruritus in which PASI response was maintained over 52 weeks with 
continued apremilast treatment. Most patients who were re-randomized to placebo 
and lost PASI75 response regained it after apremilast reinitiation. Interestingly, 
apremilast has also demonstrated improvements in the signs and symptoms of 
psoriatic arthritis and improved in nail, scalp psoriasis, physical function in those 
patients [42]. Overall, safety profile characterizing apremilast is favorable. The most 
frequently reported AEs were nausea, upper respiratory tract infection, headache and 
diarrhea, though a few cases of suicidal ideation and behavior were reported in 0.2% 
(3 of 1441) of apremilast-treated psoriatic arthritis patients (only one case in plaque-
type psoriasis patients) [43,44]. Notably, 2 placebo-treated patients committed 
suicide compared to none in the apremilast group. Moreover, among apremilast-
treated phase III patients, 1.0% of patients reported depression or depressed mood 
(placebo: 0.8%) [43,44].  
 
3.3 A3 adenosine receptor agonists 
A3 adenosine receptor agonists are (AAr) G protein-coupled receptors that are 
involved in a variety of intracellular signaling pathways and physiological functions. 
The natural ligand of AAr receptors is adenosine. AArs are highly expressed in 
peripheral blood mononuclear cells isolated from patients with psoriasis and the AAr 
activation with a specific agonist (CF101) downregulates the nuclear factor-ºB 
signaling pathway, inhibits the proliferation of specific autoreactive T lymphocytes, 
and induces apoptosis of inflammatory cells [45]. These effects result in the down-
regulation of proinflammatory cytokines, such as TNF±, IL-6, and IL-12 [46]. 
In a Phase II, multicentre, dose-ranging study, patients with moderate-to-severe 
plaque-type psoriasis were treated with CF101 (1 mg, 2 mg, or 4 mg) or placebo 
administered orally BID for 12 weeks. In the 2 mg CF101-treated group, a 
progressive improvement in the mean change from baseline in PASI versus placebo 
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13  
throughout the study period was observed, with a statistically significant difference at 
weeks 8 and 12. In this group, 35.3% of the patients achieved PASI50 response; a 
higher response rate was not achieved. Side effects reported were considered mild 
[47].  
 
4. Patented biologic agents 
The introduction of biologic agents profoundly changed the management of psoriasis 
and its therapeutic algorithm, particularly in the long-term treatment. Biologics are 
mainly represented by monoclonal antibodies neutralizing either receptors or soluble 
mediators (i.e. cytokines), receptor (i.e., cytokine receptor). The first class of biologic 
agents used in psoriasis is represented by the TNF± inhibitors. An anti-p40 IL-12/23 
agent, ustekinumab, has also been approved for the treatment of psoriasis, and other 
biologic agents targeting the same pathogenic axis will be marketed. 
 
4.1 Anti-IL23 agents 
Besides anti-TNF± inhibitors, new agents targeting other steps in the pathogenic 
cascade of psoriasis have been developed. IL-23 is a central cytokine to the 
pathogenesis of psoriasis, its main immunologic role is the involvement in the 
differentiation process of naïve Th cells into Th17. IL-23 might be targeted by: 1) anti-
p40 agents such as ustekinumab, approved for the treatment of plaque-type 
psoriasis and psoriatic arthritis, and briakinumab (abt-874), another fully humanized 
antibody that reached a pre-registration status but its development has been 
discontinued because of the increased incidence in US of major cardiovascular 
events occurring in briakinumab-treated patients; 2) anti-p19 agents like 
tildrakizumab (MK-3222), a fully human IgG1 antibody (Merck) that is in a more 
advanced status of development compared to the other three agents; and 3) IL-23R-
antagonists, which are currently being tested in preclinical studies, although no 
information yet exists regarding their biochemical structure, the status of 
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development or pharmacokinetics and pharmacodynamics features [48].  
Ustekinumab is a fully human monoclonal antibody which blocks the activity of p40, a 
protein subunit shared by IL-12 and IL-23 [49, 50]. Ustekinumab demonstrated an 
extremely favorable safety profile as showed by a meta-analysis reporting that few 
adverse events associated with the use of etanercept and adalimumab reached 
statistical significance whereas no adverse events were significantly related to 
ustekinumab use [51]. Ustekinumab has been approved for the treatment of 
moderate to severe psoriasis in 2009 by the FDA; its efficacy and safety were 
assessed in the PHONENIX-1 and PHOENIX-2, double-bind, placebo-controlled, 
clinical trials through 5 years, in patients with moderate to severe plaque psoriasis 
[52, 53]. In addition to ustekinumab, briakinumab represents another anti-interleukin-
12/23p40 monoclonal antibody [54]. Data on briakinumab are available in controlled 
phase II and III clinical trials, including two 52-week studies conducted in patients 
with psoriasis. In these studies, briakinumab treatment resulted in clinically significant 
improvements in quality of life and work productivity in adults with moderate to 
severe psoriasis [55]. 
In another phase III, 12-week study, briakinumab showed higher efficacy when 
compared to placebo and etanercept in patients with moderate to severe chronic 
plaque psoriasis [56]. 
Guselkumab (CNTO 1959, Centocor-Janssen Biotech) is a humanized IgG1 
monoclonal antibody targeting IL-23p19 subunit that is now being tested in Phase III 
clinical trial [57]. Its use has been under investigation for the treatment of 
palmoplantar pustulosis in a Phase III clinical trial, whereas a Phase I trial evaluating 
the pharmacokinetic of guselkumab comparing lyophilized and liquid formulations 
has recently been completed (Table 1).  
In a randomized, double-blind, placebo-controlled study evaluating the safety, 
tolerability, and clinical response of guselkumab, IL-23 inhibition with a single dose of 
guselkumab resulted in clinical responses in patients with moderate-to-severe 
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psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for 
psoriasis [58].  
 Tildrakizumab is a high-affinity, humanized, IgG1/º , anti-IL-23p19 monoclonal 
antibody developed for treatment of chronic plaque psoriasis [59]. The safety and 
efficacy of subcutaneous tildrakizumab has been evaluated in a 3-part, randomized, 
double-blind, phase II trial conducted in 355 adult subjects with moderate to severe 
chronic plaque psoriasis [60]. Enrolled subjects received tildrakizumab (5, 25, 100, 
200 mg) or placebo, injected subcutaneously at weeks 0 and 4 and every 12 weeks 
thereafter until week 52. Tildrakizumab was discontinued at week 52 and subjects 
were followed through week 72. The primary efficacy endpoint was PASI 75 
response at week 16. In this phase II trial tildrakizumab demonstrated superior 
efficacy versus placebo that was maintained up to 52 weeks of treatment and for an 
additional 20 weeks after cessation of study therapy [60]. It was generally safe and 
well tolerated. The clinical outcomes reported in the previous study are promising, 
although they await confirmation in the ongoing, larger Phase III trials. Another anti-
p19IL-23 agent that is currently under investigation in phase III trials, is BI-655066 
[61]. This monoclonal antibody was investigated for the treatment of moderate-to- 
severe plaque psoriasis in a Phase I randomize double-blind, placebo controlled 
clinical trial, the primary objective of this trial was the safety evaluation. Among BI-
655066 treated patients (31/39) only four serious adverse events (not considered 
treatment related) were reported; clinical improvement was reached from week 2 and 
maintained for up to 66 weeks after treatment) [62]. 
 
4.2 Agents targeting IL-17 (secukinumab, brodalumab and ixekizumab) 
Th-17 responses include the dysregulation of several cytokines, in particular IL-17A 
that shows to have a key role in the regulation of innate and adaptive immune 
pathways [63-65]. 
IL-17A is an inflammatory cytokine produced by a wide array of immune cells, 
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including CD4+ T cells, and other innate immune cells such as CD8+ T cells, ³ ´  T 
cells, mast cells, and neutrophils, at sites of skin plaques and inflamed entheses [66]. 
IL-17A, acting with other pro-inflammatory cytokines, including TNF±, leads to up-
regulation of expression of different genes associated to inflammatory response in 
different cells, as well keratinocytes and fibroblasts, leading to increased production 
of proinflammatory molecules [66]. Additionally, a recent study has shown a possible 
role of a neutrophil-keratinocyte axis in psoriasis that may involve neutrophil-derived 
IL-17, representing an early target of IL-17A-directed agents [67]. Several IL-17A 
inhibitors have shown promising results in several phase II studies, and more 
recently, in phase III RCTs on psoriasis and PsA.  
Secukinumab represents a fully human IgG1º  monoclonal antibody, which selectively 
neutralizes IL-17A [68]. Secukinumab has been investigated more largely in psoriasis 
and recently obtained the approval, by FDA and EMA, for the treatment of psoriasis 
and psoriatic arthritis. [69, 70]. Secukinumab has been also tested in Crohn’s disease 
showing poor clinical response (31% of treated patients discontinued treatment 
prematurely) showed a significant difference in favor of placebo and concerns about 
its safety profile in treating this condition [71]. Conversely to TNF inhibitors and 
p40IL-12/IL-23 blockers that may treat both disorders, warnings on secukinumab use 
in patients with Crohn’s disease have been labeled. In the treatment of psoriasis 
secukinumab was proved effective, as initially observed in two, 52-weeks, phase III 
randomized, double-blind, placebo-controlled trials, named ERASURE (Efficacy of 
Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis), and 
FIXTURE (Full Year Investigative Examination of Secukinumab versus Etanercept 
Using Two Dosing Regimens to Determine Efficacy in Psoriasis) [72]. Secukinumab 
demonstrated higher efficacy in treating psoriasis, particularly in achieving PASI 90 
and PASI 100 response, compared to both placebo and etanercept. Regarding the 
safety profile, infection rates including upper respiratory tract infection and 
nasopharyngitis were higher in patients on secukinumab than placebo group in both 
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studies, but similar to those seen in the group on etanercept [72]. Similarly, another 
head-to-head study testing secukinumab versus ustekinumab, demonstrated a higher 
efficacy of secukinumab as PASI 90, PASI 75, PASI 100, response, and DLQI 
improvement, compared to ustekinumab [73]. Secukinumab (both 300 mg and 150 
mg doses) was also tested as continuous or as-needed regimen showing non-
inferiority of retreatment “as needed” vs. fixed doses [74]. Indeed no significant 
difference were detected comparing the two groups, though PASI 75 response 
achieved after 12-week secukinumab treatment (84.4%-91.1% of treated subjects) 
was maintained throughout Week 52, more frequently in the “fixed interval” group 
(78.2%, 300 mg; 62.1%, 150 mg) compared to “retreatment as needed” group 
(67.7%, 300 mg; 52.4%, 150 mg). The potential of retreatment as needed with 
secukinumab warrants further investigation [74].  
Other clinical trials and subanalyses confirmed the preliminary data about safety and 
efficacy of secukinumab both in the short- and long- term [75-79].  
Brodalumab (AMG-827) is a fully human IgG2, monoclonal antibody that binds with 
high affinity IL17AR blocking IL-17A, IL-17E and IL-17F signaling. Clinical trials have 
been completed in rheumatoid arthritis, Crohn's disease and psoriasis [80,81]. In a 
Phase III study of patients with moderate-to-severe plaque psoriasis, brodalumab 
was investigated versus ustekinumab and versus placebo [82]. Eighty-six percent of 
the patients in the brodalumab 210 mg group achieved at least 75% improvement in 
disease severity compared to baseline after 12 weeks, whereas 70% of patients in 
the ustekinumab arm and 8.1% of patients in the placebo arm achieved 75% 
improvement [82]. However, based on reports of suicidal thoughts and behavior 
during clinical trials, brodalumab development has been halted and a re-evaluation of 
the safety profile is being processed in order to rule out these safety warnings. 
Ixekizumab (LY-2439821) is a IgG4 humanized anti-IL17 monoclonal antibody, which 
has been evaluated in a phase II, double-blind, placebo-controlled trial involving 
patients with chronic plaque psoriasis with scores of at least 12 on PASI [83,84]. 
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Patients received subcutaneous injections of 10, 25, 75 or 150 mg of ixekizumab or 
placebo at 0, 2, 4, 8, 12 and 16 weeks. The primary endpoint was the proportion of 
patients with a reduction in PASI score by at least 75% at 12 weeks. Secondary 
endpoints included the proportion of patients with a reduction in the PASI score by at 
least 90% or by 100% [84]. At 12 weeks, the percentage of patients with a reduction 
in PASI75 was significantly greater with ixekizumab 150 mg (82.1%), 75 mg (82.8%), 
and 25 mg (76.7%), than with placebo (7.7%), as was the percentage of patients with 
a reduction in the PASI score by at least 90%: 150 mg (71.4%), 75 mg (58.6%), and 
25 mg (50%) versus placebo [84]. Similarly, a 100% reduction in the PASI score was 
achieved in significantly more patients in the 150 mg group (39.3%), and the 75 mg 
group (37.9%) than in the placebo group (0%). Adverse events occurred in 63% of 
patients in both the combined ixekizumab groups and in the placebo group. The most 
common adverse events were upper respiratory infections, injection-site reactions 
and headache. No serious adverse events or major cardiovascular events were 
observed. The results of this study demonstrated that neutralization of IL-17 with 
ixekizumab may be an effective treatment for patients with chronic moderate-to-
severe plaque psoriasis [84]. Recently, ixekizumab received the approval for the 
treatment of moderate-to-severe plaque psoriasis by FDA. 
 
5. Bi-specific monoclonal antibodies 
Conventionally, therapeutic monoclonal antibodies selectively recognize one target. 
Because psoriasis pathogenesis identified multiple mediators playing a crucial role, 
novel therapeutics targeting more than one mediator could be more effective [85]. 
Inflammation is one of the histopathological aspects characterizing psoriasis together 
with epidermal hyperplasia and neoangiogenesis, thus the neutralization of two 
targets at the same time may exclusively affect the inflammatory process as occurs 
blocking both IL-17 and TNF±, or blocking both vascular endothelial growth factor 
(VEGF) and TNF±, the inhibition of neoangiogenesis and inflammation may be 
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induced.  
Fynomers are small binding proteins (7 kDa) derived from the human Fyn SH3 
domain. Fyn is a tyrosine-specific phospho-transferase that is a member of the Src 
family of tyrosine protein kinases Fynomers can be engineered to bind to any target 
of interest with high affinity and specificity [86,87]. In a study published in 2014 a 
fynomer inhibiting in vitro IL-17A was developed (Fynomer 2C1) [88]. Fynomer 2C1 
was genetically fused to the Fc part of a human antibody via four different amino acid 
linkers to yield bivalent binding proteins; the 2C1-Fc fusion protein with the longest 
linker displayed the most potent anti-IL17 inhibitory activity. Furthermore, in the same 
study it has been shown that in a mouse model of acute inflammation, the most 
potent 2C1-Fc fusion protein was able to efficiently inhibit IL-17A in vivo. According to 
these evidences, Fynomer-Fc fusion proteins represent new drug candidates for the 
treatment of IL-17A mediated inflammatory conditions including psoriasis [89]. 
Recently, a novel drug called Valpha, which is a chimeric fusion protein inhibiting 
both VEGF and TNF± simultaneously, has been tested in a mouse model of 
psoriasis [90]. Valpha showed superior relief effects in a psoriasis model with regard 
to epidermal thickness and the area of blood and lymphatic vessels. Thus, the 
simultaneous blocking of VEGF-A and TNF± using Valpha could be an effective 
therapeutic strategy for psoriasis [91]. 
Together with TNF±, another cytokine, namely IL-17A, is recognized as central to the 
development and progression of inflammatory diseases. Therapeutics, which are 
able to simultaneously inhibit TNF± and IL-17A, represent the next generation of 
biologic agents and they are expected to be more effective than current monospecific 
therapies. 
The FynomAb COVA322 (Covagen Pharmaceuticals) is one of them. It consists of a 
fully human, clinically validated anti-TNF± antibody and anti-IL-17A fynomers, 
genetically fused to C-terminal light-chains of the antibody [92]. COVA322 inhibits 
with picomolar potency TNF± and IL-17A at the same time. COVA322 is currently 
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under investigation in a Phase Ib/IIa clinical trial in patients with stable chronic 
moderate-to-severe plaque psoriasis (Table 1). 
 
6. Other targets 
Itolizumab is a novel humanized monoclonal antibody which targets CD6, a T-cell 
costimulator molecule, involved in T cells proliferation, signaling, gene expression 
and cytokines secretion [93, 94].  
Itolizumab resulted effective and safe for the treatment of moderate-to-severe chronic 
plaque psoriasis, in a 52-week phase III, double-blind, randomized, placebo-
controlled, parallel-arm, multicenter clinical trial, performed in twenty centers across 
India [95]. Two-hundred and twenty-two patients were randomized (2:2:1) to two 
different itolizumab arms A or B. The arm A received a 4-week loading dose of 0.4 
mg/kg/wk followed by 1.6 mg/kg every 2 weeks. The arm B received 1.6/mg every 2 
weeks. The arm C received placebo. At week 12, the placebo arm was switched to 
1.6 mg/kg itolizumab every 2 weeks. The primary end point was the proportion of 
patients with at least 75% improvement in PASI score at week 12 [95]. The main 
secondary assessment was PGA. Quality-of-life assessments were also performed, 
using SF-36 and DLQI. Histopathology was evaluated: T-cell infiltration, rete 
thickness, and epidermal thickness in psoriatic lesions were measured. T cells were 
visualized in 7- to 8-µm sections using antihuman CD3 staining. One-hundred and 
ninety-nine patients (88.4%) completed week 28 and one-hundred and seventy-one 
patients (76.0%) completed the entire study (until week 52). Other than PASI score 
less than 50 at week 28, the common reasons for withdrawal were lost to follow-up 
(10 [4.4%]), withdrawal of consent (7 [3.1%]), and disease progression or relapse (7 
[3.1%]). Five patients (2.2%) withdrew for adverse events (mostly, infusion reactions) 
[95]. A total of 27.0% in arm A, 36.4% in arm B, and 2.3% in arm C met the primary 
end point (achieved a PASI75 response at week 12) [95]. The difference from 
placebo was statistically significant (P = .0172 for A and .0043 for B). The induction 
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regimen (arm A) did not demonstrate additional benefit. Improvement was seen in 
arm C after crossover to itolizumab at week 12 [95]. Responders continued to 
increase in arms A and B from week 12 to week 28. Improvements over placebo 
were seen for T-cell infiltration and epidermal thickness at week 12, and in all arms at 
week 28.  
Itolizumab showed comparable efficacy to existing therapies, excellent safety, and 
measurable improvements in quality of life [95]. 
 
 
7. Conclusion 
Psoriasis is a debilitating disorder whose treatment has been profoundly modified by 
the identification of different therapeutic targets: cytokines and their receptors, cell 
surface antigens, transcription factors, and other intracellular signal transducers. The 
first one to be effectively targeted was TNF±. More recently, cytokines sharing the 
p40 subunit, namely IL-12 and IL-23, were thought to play an important role in 
psoriasis leading to the development of the antibodies targeting p40. As the 
pathogenesis of psoriasis evolved and the importance of the IL-23/IL-17 axis has 
emerged, at least three antibodies targeting IL-17 or its receptor have been clinically 
tested. Thus, advances in both knowledge and drug development led to new 
therapies that are more selective and more effective, maintaining very high standards 
of safety compared to previously approved biologic agents. Antibodies Therapeutic 
monoclonal antibodies or fusion proteins neutralizing cytokines, cytokine subunits, or 
receptors will represent part of the future therapeutic armamentarium that will be 
completed by small molecule drugs.  
 
8. Expert opinion 
Psoriasis vulgaris is a chronic condition wherein effective and safe therapies are 
needed for long-term use. Treatments available for psoriasis have rapidly increased 
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in recent years. Nevertheless, many of them may have serious side effects, in 
particular in the long-term. Being a chronic condition, a favorable long-term safety 
and efficacy profile should represent the most critical hallmark for an antipsoriatic 
agent. New advances in the understanding of psoriasis pathogenesis led to the 
development of new drugs that are produced through biotechnology. These products 
seem to be more effective and safe for long-term compared to conventional 
therapies. There will be several new options for the treatment of psoriasis in the 
upcoming years. Patented drugs and, the therapeutic paradigm will be further 
expanded by the emerging targets herein reported that have not been long enough 
studied to ascertain any uncommon AEs and long-term efficacy that may be 
associated with these new agents.  
Because, PASI 90 and PASI 100 are currently considered a successful therapeutic 
response, the primary goal of the latest patented monoclonal antibodies is clearing 
skin, reaching a PASI score improvement of at least 90% with respect to baseline 
PASI [96]. Particularly, the anti-IL-17 agents obtained a strikingly high clinical 
response in treating psoriasis, showing superior efficacy compared to marketed 
biologic agents. This superiority has been convincingly demonstrated by various 
head-to-head trials testing anti-IL-17 agents versus either a TNF inhibitor 
(etanercept) or an anti-p40 agent (ustekinumab). The introduction of anti-IL17 drugs 
in clinical practice bears the promise of achieving at least PASI90 response in a 
consistent portion of treated patients.  
Notably, neither TNF± nor IL-17 blockers are able to obtain a satisfactory response in 
100% of patients. This evidence may have important implications as it might 
represent the result of alternative pathogenic circuits that are not driven by the 
targeted mediator. Thereby, newest therapeutic antibodies neutralizing more than 
one cytokine may have the advantage of contemporarily blocking multiple key steps 
of the pathogenic cascade conversely to one-cytokine-blocking antibody. As 
previously showed, IL-17 and TNF± synergistically act in mediating the key 
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inflammatory circuits in psoriasis [16], thus, it would be of interest testing the efficacy 
of these antibodies bispecific for both IL-17 and TNF±. On the other hand, small 
molecules will not have the same efficacy as biologics, but they show some important 
advantages: they are orally available and easier to produce. According with their 
mechanism of action, small molecules could potentially expand the oral treatment 
armamentarium for psoriasis, either as monotherapy or combined with topical, 
systemic or biologic therapies. It would be of interest to study combinations of small 
molecules with other antipsoriatic therapeutics. Considering the therapeutic 
armamentarium available and the future therapeutic scenario, biosimilars need to be 
mentioned, though they are off-patented drugs. Biosimilars show an identical primary 
amino acid sequence, dose, route of administration, compared to the originators, 
whose patent expired. They need to prove comparable pharmacokinetics, 
pharmacodynamics, safety and efficacy with the reference products. Nevertheless, 
the clinical development program is usually smaller compared to a new biologic 
agent because comparability trials may be performed on a smaller and “sensitive” 
study population, and the originator’s indications may be extrapolated. By definition, 
biosimilars cannot give any advantage (except for the price) compared to their 
originators; otherwise they would represent “biobetter” products with significant 
implications in terms of drug development, as they would be considered as a brand-
new agent. Thereby, the introduction of biosimilars will not expand the antipsoriatic 
drug array but it will affect health care costs. Among biosimilar class of TNF-agents, 
infliximab biosimilars are actually available in the market. Pharmaceutical companies 
received approval for their infliximab biosimilar in Europe in September 2013 and it 
has been approved by EMA for the same indications as Remicade (inflixmab), i.e. 
ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid 
arthritis, and ulcerative colitis. Since small molecular differences (i.e., glycosylation) 
may affect safety and immunogenicity, tracking of adverse events associated with the 
use of both reference and biosimilar products, and the ability to readily identify the 
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manufacturer and the product name is an issue that must be addressed.  
Undoubtedly, the introduction of new-patented drugs blocking in a different manner a 
well known key-player in psoriasis or targeting alternative mediators (i.e., 
guselkumab, apremilast, tofacitinib, ixekizumab) could definitely represent a relevant 
benefit and support to treat patients non-responders or contraindicated to current 
antipsoriatic therapies. Preliminary data from multiple clinical trials suggested that 
higher selectivity in blocking the IL-23/IL-17 axis reflects greater efficacy maintaining 
a favourable safety profile. A straightforward example is provided by a head-to-head 
study recently presented at the last American Academy of Dermatology testing an 
anti-p19IL-23 agent (BI-655066) vs. an anti-p40IL-12/IL-23 agents (ustekinumab). 
The sharper neutralization of IL-23 activity by BI-655066, avoiding the suppression of 
IL-12 signalling, obtained higher clinical response in terms of PASI 90, PASI 100, and 
static Physician Global Assessment (sPGA), compared to ustekinumab [97]. Limited 
long-term clinical data for certain drugs, and the complete lack of clinical outcomes 
for the bispecific biologic agents, do not allow the definition of the future therapeutic 
paradigm. Likely, the introduction of IL-17 blockers will increase the opportunity to 
treat patients, providing an important chance not only for biologic-naïve patients, but 
also to those unresponsive to the current biologic drugs. To the light of recent and 
forthcoming approvals for various therapeutics, including apremilast, tildrakizumab, 
and guselkumab, and considering the future bispecific molecules approaching a later 
phase of development, the traditional therapeutic algorithm will profoundly change 
and it is difficult, now, to be defined.  
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Table 1. Therapeutic agents patented in 2010-2015. 
 
Agent Description Phase of 
Development for 
psoriasis 
Patent  
Tofacitinib JAK1 and JAK3 
inhibitor 
Phase III  WO2012137111A1 
(2012)26 
Ruxolitinib JAK1 and JAK2 
inhibitor 
Phase III WO2013188783A1 
(2013)33 
Baricitinib JAK1 and JAK3 
inhibitor 
Phase IIb US20150118229A1 
(2015)36 
Apremilast PDE-4 inhibitor Marketed by FDA WO2012149251A1 
(2012 )37  
CF101 A3 adenosine 
receptor agonist 
Phase III WO2011027348A1 
(2011)43 
Fynomer 2C1 Fynomer inhibiting 
IL-17A 
Pre-clinical US20130005659A1 
(2013)52 
Valpha Bispecific chimeric 
fusion protein 
inhibiting VEGF and 
TNF±  
Pre-clinical US8927232B2. 
(2015)54  
COVA322 Bispecific fynomer 
inhibiting TNF± and 
IL-17A 
Phase II EP2597102A1 
(2013)56 
Briakinumab 
(ABT-874) 
Anti-interleukin-
12/23p40 
monoclonal 
Development 
discontinued (phase 
III) 
US9051368B2 
(2015) 
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antibody 
Guselkumab 
(CNTO 1959) 
Anti-IL-23p19 
subunit monoclonal 
antibody 
Phase III WO2014004436A2 
(2014)65 
Tildrakizumab Anti-IL-23p19 
subunit monoclonal 
antibody 
Phase III WO2013009535A1 
(2013)66 
Secukinumab Anti-IL-17 
monoclonal 
antibody 
Pre-marketing WO2012045848A1 
(2012)72 
Brodalumab 
(AMG-827) 
IL17AR blocking 
monoclonal 
antibody 
Phase III WO2011046958A1 
(2011)83 
Ixekizumab 
(LY-2439821) 
Anti-IL17 
monoclonal 
antibody 
Phase III US2014341888A1 
(2014)86 
Itolizumab CD6 blocking 
monoclonal 
antibody 
Phase III WO2015011658A1 
(2015)88 
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